Articles tagged with Antibodies
A University of Houston team, with a NIH grant, is creating a quick, accurate test for the 'Cruise Ship Virus' using retroreflectors and antibody proteins. The tool has the potential to diagnose diseases like Norwalk more easily and may be applied to other infectious diseases.
A novel gene therapy could provide a permanent genetic cure for hemophilia A patients, including those with expensive and ineffective treatments. The treatment involves cloaking Factor VIII in platelets to avoid antibody attacks, making it effective even in patients with inhibitory antibodies.
Scientists at Rice University and M.D. Anderson Cancer Center have developed a method to load multiple anticancer drugs into a single antibody, increasing the effectiveness of chemotherapy. The use of buckyballs, soccer ball-shaped molecules of pure carbon, allows for the creation of targeted therapeutics with unique properties.
Researchers compared wild rodents to laboratory rodents and found that wild animals had higher levels of antibodies associated with allergy and autoimmune disease. This suggests that a lack of exposure to microbes in modern environments may contribute to these conditions.
Researchers found that 48% of participants reported no or very little microvascular complications, and that some patients still have residual islet function. The study suggests that many patients with long-term type 1 diabetes may have some residual insulin production, paving the way for new treatments.
A new NIAID study found that a higher dose of flu vaccine significantly increases the immune responses of older adults, providing hope for better protection against seasonal influenza. The trial showed that participants who received a high-dose vaccine had 44-79% higher levels of antibody than those who received the standard dose.
Researchers have developed a 3D modeling technique that shows how antibodies bind to bacterial sugars, allowing for potential new vaccines. This technique can be used to create new vaccines that protect against multiple strains of bacteria.
Researchers have created a heat-stable antibody that can detect caffeine in various drinks, including coffee, tea, and cola. The test has shown accuracy comparable to sophisticated equipment, with potential applications for consumers who want to avoid caffeine due to health or personal reasons.
A new home testing kit could help identify 'hidden' caffeine in coffee, tea, and soda by detecting the stimulant in hot beverages. The test strips use an unusual antibody derived from llamas that is resistant to high temperatures, allowing for accurate detection of caffeine content.
Researchers found a significant association between Epstein-Barr virus infection and multiple sclerosis (MS), with elevated antibody levels before symptom onset. The study suggests Epstein-Barr virus may predispose individuals to autoimmunity, paving the way for new treatments and prevention strategies.
Adult stem cells can make new tendon tissue and repair damaged tendons in rats. The study demonstrates potential for using this technology to treat musculoskeletal injuries and degenerative diseases.
A study found that Vesivirus antibodies were present in over 40% of patients with clinical hepatitis, suggesting a potential link between the virus and human disease. The research also highlights the widespread distribution of Vesivirus in various animal species, including fish and primates.
A recent study found that antibodies targeting the Chagas parasite also block rhodopsin, a molecule essential for converting light into electrical impulses. This discovery sheds light on the molecular mechanisms underlying the disease's vision problems. Researchers hope to develop new drugs or vaccines to combat the parasite and improv...
Scientists at Georgia Tech have developed reusable hydrogel microlenses that can detect trace amounts of biological or chemical agents in a matter of seconds. These tiny lenses use antibody-antigen binding to change their focus when exposed to the target substance, enabling rapid detection and identification.
Researchers at UC Berkeley have successfully forced a benign virus to evolve into a more effective delivery vehicle for genes in gene therapy. By accelerating the process of viral evolution, they were able to bypass the immune system's defenses and increase the virus's ability to deliver genes to target cells.
A study of 41 adults with X-linked agammaglobulinemia found that most can function as relatively healthy individuals despite chronic, low-grade infections. Patients reported good health and quality of life, with many working full-time or attending school.
Researchers at Yale University School of Medicine used Automated Quantitative Analysis (AQUA TM ) technology to standardize biomarker detection methods. The study found that antibody concentration can dramatically alter the relationship between biomarker levels and clinical outcome, particularly for breast cancer biomarkers.
Researchers find that different antibody isotypes bind to specific receptors on immune cells, determining their effectiveness in fighting tumors and viruses. The discovery opens up new possibilities for improving antibody-mediated cancer therapy and viral treatment.
Researchers found a nearly twofold greater risk of death or hospitalization extending longer than 10 days for patients with heparin antibodies before surgery. The study also showed that patients with the antibodies fared worse than those without, regardless of their predicted surgical risk.
A new high-affinity antibody successfully eliminated anthrax bacteria and its deadly toxins in animal tests, offering a promising treatment for late-stage anthrax infection. The antibody produced in bacterial cells could lead to a simpler and cheaper way to treat anthrax, providing an effective treatment that doesn't require antibiotics.
A new study published in Clinical Pharmacology and Therapeutics found that a nicotine vaccine was safe and well-tolerated in helping smokers quit. The vaccine, which works by producing antibodies that bind to nicotine, showed impressive results with 38% of participants quitting for at least 30 days.
Researchers developed a vaccine platform offering protection against pneumocystis, influenza, and other pathogens in immunocompromised individuals. The vaccine uses a specific antigen and CD40L molecule to induce an immune response.
A new antibody profiling technique has been developed to identify five protein markers that can detect lung cancer with high accuracy. The technique achieved 90% sensitivity and 95% specificity in identifying cancerous versus non-cancerous patient samples.
Researchers at UCLA have identified how an antibody blocks prostate cancer growth by signaling cells to stop growing and die. The discovery could lead to a new treatment targeting prostate stem cell antigen, also found in bladder and pancreatic cancers.
A team of scientists at Sanford Burnham Prebys found that an antibody produced in reaction to a naturally-occurring sugar chain curbs intestinal inflammation induced in mice, reversing early symptoms and halting disease progression. The research holds promise for treating Crohn's disease and other inflammatory disorders.
Researchers have developed a faster method to create antibodies for disease research, enabling the study of proteins at a higher rate. The new technique uses synthetic peptide immunisation and binds specifically to proteins with a precise sequence, producing highly specific antibodies.
Researchers at Yale University have developed two ways to induce MS symptoms in mice, revealing a key distinction between disease-causing and non-disease antibodies. The study brings the team closer to pinpointing accurate diagnostic tools for individual MS patients.
The BEADS system detects toxin from environmental samples, then uses antibodies to purify and concentrate the pathogen or toxin for accurate detection. The system has been commercially licensed and can detect multiple pathogens simultaneously.
A study found a strong relationship between HCV infection and having an anti-HCV positive family member, with the highest incidence rate in children under 10 living in households with an anti-HCV positive parent. Parenteral exposures increased the risk of HCV, particularly in men married to an HCV positive woman.
Researchers discovered specific mutations in the TACI gene that are associated with common variable immunodeficiency and IgA deficiency. These genetic defects impair the immune system's ability to fight infections, increasing the risk of recurrent illnesses and autoimmune diseases.
David M. Goldenberg, a pioneer in radiolabeled antibodies, has received the Society of Nuclear Medicine's 2005 Paul C. Aebersold Award. He has developed antibodies for various cancer types and therapies, making significant contributions to nuclear medicine.
Scientists at UCSD and Elan Pharmaceuticals have successfully vaccinated mice with a combination of human alpha-synuclein protein and adjuvant, reducing abnormal alpha-synuclein accumulation and promoting nerve cell survival.
A new study found that a combination of immunosuppressive therapies significantly reduces non-cellular and humoral rejection in heart transplant recipients. The TAC/MMF group showed the lowest incidence of any treated rejection and improved side effects compared to other groups.
Researchers develop customized antibodies that work together to target and destroy cancer cells. The therapy shows significant synergy, with a single combination of antibodies leading to more than three times greater effectiveness than a solo antibody in inhibiting HER2 signaling.
Researchers at the Weizmann Institute have developed a new technology that uses allicin to target and destroy cancer cells. By attaching the enzyme alliinase to an antibody already in clinical use, they can deliver a continuous supply of allicin to penetrate and kill cancer cells.
Researchers have discovered that natural protection against pneumococcal disease may not rely solely on antibodies. Long-lasting immunity to pneumococcus was found in mice exposed to live bacteria or a whole-cell vaccine, which stimulates CD4+ T-cells to provide protection at the earliest stage of infection.
Researchers developed plant-derived antibodies that protect against anthrax infection, providing immediate protection and a safe alternative to traditional vaccination methods. The plant-produced antibodies can be used before or after exposure and are stable for long periods, making them an attractive solution for stockpiling.
Researchers discovered that methamphetamine triggers an immune response by forming antibodies, leading to increased tolerance and binge behavior. This finding may lead to the development of specific antibodies as a clinical treatment for addiction.
A new study found that genetic amplification (NAAT) testing detects HIV more effectively than standard antibody testing in urban settings. The test identified four individuals with acute HIV infections who had previously tested negative, highlighting its potential to prevent transmission and improve early detection.
Researchers found that clearing Alzheimer's plaques leads to rapid recovery of normal brain structure in just three days. The study suggests that plaque-clearing treatments may slow or halt disease progression, and researchers plan to investigate the underlying mechanisms.
Researchers used PGD to select an RhD- embryo, resulting in a healthy baby girl. The technique aims to alleviate the risk of haemolytic disease of the fetus or newborn associated with RhD alloimmunization.
Researchers at Weill Cornell Medical College have developed a fast-acting anthrax vaccine that uses gene transfer technology to provide rapid immunity. The new vaccine works quickly, granting mice immunity within 12 to 18 hours of vaccination and may be used in combination with active vaccines for enhanced protection.
Researchers have discovered a link between DNA movement and the formation of antibody genes in specialized blood cells. The study found that a specific type of transposable element is involved in both DNA recombination mechanisms, shedding light on their relationship and potential role in cancer development.
Researchers successfully silenced SDF-1's signal in mice with simulated retinopathy, effectively halting the growth of new blood vessels. The study could lead to a treatment option using routine injections of an antibody-blocking substance into a patient's eye.
Researchers found that old T cells weaken the immune system in older mice, causing impaired B cell activation and antibody production. However, infusing young T cells into old mice restored B cell function, suggesting a key role for helper T cells in maintaining immune capacity with age.
The HMS vaccine, dl5-29, outperformed two established vaccines in animal models, demonstrating a stronger T cell response and broader antibody protection. The results suggest that dl5-29 is the most compelling new vaccine candidate for genital herpes, with potential to prevent infection and recurring disease.
A 12-center study found that an immune-modulating therapy, IVIG, reduces high antibody levels and improves transplantation rates in highly sensitized patients. The study showed a significant benefit of IVIG over placebo, with transplant rates more than double for the treatment group.
A new antibody treatment has shown promise in slowing or halting Crohn's disease by blocking the production of inflammatory proteins. The treatment was safe and effective in reducing symptoms in patients with active Crohn's disease.
Researchers found that injecting antibodies directly into the brain of mice slowed down plaque growth by up to two months without adverse side effects. This modified passive immunization method may offer a safer treatment option for Alzheimer's, providing a window for other treatments to prevent new plaque formation.
Researchers discovered a critical link in the molecular pathway that enables the immune system to target invaders with precision. The discovery may also provide new information on lymphoma, a type of leukemia where certain immune cells proliferate uncontrollably.
Researchers found that specific immunoglobins 'turn on' the IGF-1R, triggering inflammation and T lymphocyte activation. Blocking this interaction arrests molecular events leading to T cell activation, offering promise for a common therapeutic strategy for autoimmune diseases.
Scientists at Boston Children's Hospital have uncovered a crucial mechanism that enables B cells to produce unique, specialized antibodies by selectively targeting specific stretches of DNA. This discovery has significant implications for understanding the immune system and potentially preventing cancers like lymphomas.
Visilizumab shows promise in treating severe ulcerative colitis by blocking processes that lead to colon inflammation and damage. The new therapy offers an alternative to invasive surgery for patients with severe UC.
Researchers have developed a method that could vastly improve the ability of atomic force microscopes to 'see' the chemical composition of a sample, follow variations of the sample, and map its topographic structure. This new technique allows for molecular-scale imaging with increased sensitivity.
Researchers found that immune therapy against Alzheimer's disease not only removes the toxic amyloid plaque but also clears protein tangles, suggesting a broad assault on the disease. The treatment was shown to clear both hallmark lesions of AD by alleviating interference in the cell's protein garbage disposal system.
Researchers recommend performing oral food challenges on children with at least a 50-50 chance of passing, based on IgE antibody levels less than 2.0 kilounits per liter of blood. This guideline aims to reduce unnecessary avoidance of common allergenic foods and improve the accuracy of food allergy diagnosis.
A recent study found that B-cell targeted therapy significantly reduced arthritic symptoms in patients, with improvement lasting over a year and sometimes up to three years. The treatment has shown promise in breaking the cycle driving the disease, but further studies are needed to ensure its safety.
A small trial found that daclizumab add-on therapy reduced the severity and number of brain lesions in patients with relapsing-remitting or secondary progressive multiple sclerosis. The treatment, which blocks the interleukin-2 receptor on immune cells, showed unexpected clinical benefits in a small group of patients.
Researchers at VIB have developed nanobodies, tiny proteins that can target specific cancer cells. These nanobodies have shown promise in treating various diseases, including inflammatory and heart conditions.
Researchers have developed a second-generation targeted antibody, 806, which shows potent anti-tumor activity in animal models of human cancers that overexpress EGFR. The antibody binds specifically to activated EGFR on cancer cells, avoiding normal tissues.